Department of Pharmacy, King Saud Medical Complex, Riyadh, Saudi Arabia.
Appl Health Econ Health Policy. 2013 Dec;11(6):671-5. doi: 10.1007/s40258-013-0065-6.
The prevalence of diabetes mellitus continues to increase globally. Furthermore, it is projected that healthcare expenditure on this epidemic will mount to US$490 billion in 2030. Information on the economic burden of diabetes care in Saudi Arabia is largely lacking.
This retrospective observational study evaluated the direct medical cost of type 2 diabetes mellitus (T2DM) in a Saudi population in relation to glycemic control at a governmental institution from a payer's perspective.
Three hundred subjects attending a university hospital were classified into three groups (n = 100 each) based on HbA1c values to <7 %, 7-9 %, and >9 %. The total direct medical costs were calculated for drug therapy, diagnostic procedures, hospitalization, and outpatient visits. The year of valuation for the costings was 2010/2011.
The total annual direct medical cost per group was found to be US$1,384.19 for HbA1c <7 %, US$2,036.11 for HbA1c 7-9 %, and US$3,104.86 for HbA1c >9 % (p < 0.001). There was also a statistically positive relationship in the total care cost of diabetic patients and the number of co-morbidities (p < 0.001). A direct association of the cost of medications that have been disbursed for diabetic patients and the medical specialty of the treating physician (r = 0.390; p < 0.0001), and the cost of laboratory analyses (r = 0.351; p < 0.0001), was observed as also between the cost of laboratory diagnosis and days of hospitalization (r = 0.478; p < 0.0001). Multivariate analysis showed that the relationship between HbA1c and total cost is independent of age and gender, while co-morbidities remain as a significant predictor for the total cost.
Collectively, the estimated direct annual medical cost of diabetes care in Saudi Arabia would be enormous. The current study offers more insight into the economic burden of diabetes on the country.
全球范围内糖尿病的患病率持续上升。此外，预计到 2030 年，针对这种流行病的医疗保健支出将达到 4900 亿美元。关于沙特阿拉伯糖尿病护理经济负担的信息在很大程度上是缺乏的。
本回顾性观察性研究从支付者的角度评估了沙特阿拉伯某政府机构中 2 型糖尿病（T2DM）患者的血糖控制与直接医疗费用之间的关系。
根据 HbA1c 值将 300 名就诊于一所大学医院的患者分为三组（每组 100 例），HbA1c 值分别为<7%、7-9%和>9%。计算药物治疗、诊断程序、住院和门诊就诊的总直接医疗费用。成本计价的年份为 2010/2011 年。
发现每组的年直接医疗费用分别为 HbA1c<7%为 1384.19 美元、HbA1c 为 7-9%为 2036.11 美元、HbA1c>9%为 3104.86 美元（p<0.001）。糖尿病患者的总护理费用与合并症的数量之间也存在统计学上的正相关关系（p<0.001）。观察到用于糖尿病患者的药物费用与治疗医生的医疗专业之间存在直接关联（r=0.390；p<0.0001），以及实验室分析费用与住院天数之间存在直接关联（r=0.351；p<0.0001）。多变量分析显示，HbA1c 与总费用之间的关系独立于年龄和性别，而合并症仍然是总费用的重要预测因素。
总体而言，沙特阿拉伯糖尿病护理的直接年度医疗费用将是巨大的。本研究更深入地了解了糖尿病对该国的经济负担。
